Iloprost improves survival of ischemic experimental skin flaps.
The ability of the prostacyclin analogue iloprost to improve survival of ischemic experimental skin flaps was investigated. Unilateral island skin flaps based on the superficial inferior epigastric vessels were raised in 70 rats and subjected to varying lengths of primary ischemia. The flaps were divided into the following four groups: group I, no perfusion washout; group II, postischemic washout with lactated Ringer's solution; group III, postischemic washout with urokinase; and group IV, postischemic washout with iloprost. Flap survival rates for group IV were significantly higher than all other groups (p < 0.05). The primary ischemia time at which 50% of the flaps failed was 8.9 hours for group I, 9.5 hours for group II, 13.3 hours for group III, and 15.3 hours for group IV. This is the first study to investigate the effect of iloprost on skin flap survival. Iloprost was found to be significantly more effective than urokinase in salvaging ischemic experimental skin flaps.
Senderoff
D M
DM
Department of Surgery, Mount Sinai Medical Center, New York, NY.
Israeli
D
D
Zhang
W X
WX
Urken
M L
ML
Weinberg
H
H
D000818:Animals; D011464:Epoprostenol / Q000502:physiology; D005260:Female; D006085:Graft Survival / Q000187:drug effects* / Q000502:physiology; D016285:Iloprost / Q000494:pharmacology*; D007511:Ischemia / Q000503:physiopathology*; D007552:Isotonic Solutions / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D000077325:Ringer's Lactate; D012867:Skin / Q000098:blood supply*; D013524:Surgical Flaps / Q000502:physiology*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D007552:Isotonic Solutions; D000077325:Ringer's Lactate; D011464:Epoprostenol; D014568:Urokinase-Type Plasminogen Activator; D016285:Iloprost